UROGEN PHARMA LTD's ticker is URGN and the CUSIP is M96088105. A total of 60 filers reported holding UROGEN PHARMA LTD in Q2 2018. The put-call ratio across all filers is - and the average weighting 1.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,246 | +193.2% | 160,300 | +116.6% | 0.00% | +300.0% |
| Q2 2023 | $766 | +72.5% | 74,000 | +54.2% | 0.00% | 0.0% |
| Q1 2023 | $444 | +15.6% | 48,000 | +10.9% | 0.00% | 0.0% |
| Q4 2022 | $384 | -99.9% | 43,300 | +0.5% | 0.00% | 0.0% |
| Q3 2022 | $359,000 | +0.6% | 43,100 | -1.1% | 0.00% | – |
| Q2 2022 | $357,000 | +66.0% | 43,600 | +76.5% | 0.00% | – |
| Q1 2022 | $215,000 | -63.6% | 24,700 | -24.7% | 0.00% | -100.0% |
| Q4 2020 | $591,000 | +99.7% | 32,800 | +310.0% | 0.00% | – |
| Q1 2019 | $296,000 | -62.7% | 8,000 | -52.4% | 0.00% | -100.0% |
| Q3 2018 | $793,000 | -94.1% | 16,800 | -93.8% | 0.00% | -85.7% |
| Q2 2018 | $13,531,000 | +73.8% | 272,151 | +73.7% | 0.01% | -22.2% |
| Q1 2018 | $7,786,000 | +59.6% | 156,700 | +19.5% | 0.01% | +80.0% |
| Q4 2017 | $4,878,000 | +504.5% | 131,100 | +412.1% | 0.01% | +400.0% |
| Q3 2017 | $807,000 | – | 25,600 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| GREAT POINT PARTNERS LLC | 2,620,545 | $36,713,835 | 6.69% |
| Wildcat Capital Management, LLC | 495,606 | $6,943,440 | 2.79% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 508,883 | $7,129,451 | 2.16% |
| Opaleye Management Inc. | 320,000 | $4,483,200 | 1.46% |
| AlphaCentric Advisors LLC | 165,000 | $2,311,650 | 1.31% |
| Soleus Capital Management, L.P. | 372,000 | $5,211,720 | 0.48% |
| EAM Investors, LLC | 170,523 | $2,389,027 | 0.46% |
| RA Capital Management | 1,483,697 | $20,786,595 | 0.41% |
| Parkman Healthcare Partners LLC | 145,311 | $2,035,807 | 0.37% |
| MENORA MIVTACHIM HOLDINGS LTD. | 2,303,031 | $32,265,464 | 0.29% |